Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor

References

• Organization WH. Mental Health in the Workplace. 5, 2019.
   Google Scholar
• Al-HarbiKS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388. doi:10.2147/PPA.S2971622654508
   PubMed Web of Science ®Google Scholar
• JamesSL, AbateD, AbateKH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.30496104
   PubMed Web of Science ®Google Scholar
• MiskowiakKW, VinbergM, HarmerCJ, EhrenreichH, KessingLV. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology. 2012;219(3):687–698. doi:10.1007/s00213-011-2511-121947319
   PubMed Web of Science ®Google Scholar
• MiskowiakKW, VinbergM, ChristensenEM, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled Phase 2 trial. Neuropsychopharmacology. 2014;39(6):1399–1408. doi:10.1038/npp.2013.33524322509
   PubMed Web of Science ®Google Scholar
• MiskowiakKW, VinbergM, MacoveanuJ, et al. Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry. 2015;78(4):270–277. doi:10.1016/j.biopsych.2014.12.01325641635
   PubMed Web of Science ®Google Scholar
• ShirayamaY, ChenAC-H, NakagawaS, RussellDS, DumanRS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22(8):3251–3261. doi:10.1523/JNEUROSCI.22-08-03251.200211943826
   PubMed Web of Science ®Google Scholar
• GirgentiMJ, HunsbergerJ, DumanCH, SathyanesanM, TerwilligerR, NewtonSS. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry. 2009;66(3):267–274. doi:10.1016/j.biopsych.2008.12.00519185286
   PubMed Web of Science ®Google Scholar
• GoldwasserE. Erythropoietin and its mode of action. Blood Cells. 1984;10(2–3):147–162.
   PubMedGoogle Scholar
• SyedRS, ReidSW, LiC, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395(6701):511–516. doi:10.1038/267739774108
   PubMed Web of Science ®Google Scholar
• PunnonenJ, MillerJL, CollierTJ, SpencerJR. Agonists of the tissue-protective erythropoietin receptor in the treatment of parkinson’s disease. Curr Top Med Chem. 2015;15(10):955–969. doi:10.2174/15680266151015032822452725832721
   PubMed Web of Science ®Google Scholar
• LeistM, GhezziP, GrassoG, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305(5681):239–242.15247477
   PubMed Web of Science ®Google Scholar
• SathyanesanM, WattMJ, HaiarJM, et al. Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry. 2018;8(1):113. doi:10.1038/s41398-018-0168-929884778
   PubMed Web of Science ®Google Scholar
• TiwariNK, SathyanesanM, SchweinleW, NewtonSS. Carbamoylated erythropoietin induces a neurotrophic gene profile in neuronal cells. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:132–141. doi:10.1016/j.pnpbp.2018.07.01130017780
   PubMed Web of Science ®Google Scholar
• SampathD, McWhirtJ, SathyanesanM, NewtonSS. Carbamoylated erythropoietin produces antidepressant-like effects in male and female mice. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109754. doi:10.1016/j.pnpbp.2019.10975431454554
   PubMed Web of Science ®Google Scholar
• PhillipsJC, WangW, GumbartJ, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781–1802. doi:10.1002/jcc.2028916222654
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE) 2013;08. Chemical Computing Group ULC SSWS. Montreal, QC, Canada; 2018:H3A 2R7.
   Google Scholar
• PekasNJ, NewtonSS. Computational analysis of ligand-receptor interactions in wild-type and mutant erythropoietin complexes. Adv Appl Bioinform Chem. 2018;11:1–8. doi:10.2147/AABC.S17720630410371
   PubMedGoogle Scholar
• DmytriyevaO, BelmeguenaiA, BezinL, et al. Short erythropoietin-derived peptide enhances memory, improves long-term potentiation, and counteracts amyloid beta-induced pathology. Neurobiol Aging. 2019;81:88–101. doi:10.1016/j.neurobiolaging.2019.05.00331255922
   PubMed Web of Science ®Google Scholar
• BrinesM, PatelNS, VillaP, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105(31):10925–10930. doi:10.1073/pnas.080559410518676614
   PubMed Web of Science ®Google Scholar
• CeritH, VeerIM, DahanA, et al. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol. 2015;25(12):2289–2299. doi:10.1016/j.euroneuro.2015.09.00526431906
   PubMed Web of Science ®Google Scholar
• TsudaE, KawanishiG, UedaM, MasudaS, SasakiR. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem. 1990;188(2):405–411. doi:10.1111/j.1432-1033.1990.tb15417.x2156701
   PubMedGoogle Scholar
• DahanA, BrinesM, NiestersM, CeramiA, van VelzenM. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016;1(1):e566. doi:10.1097/PR9.000000000000056629392190
   PubMedGoogle Scholar
• Cheung Tung ShingKS, BroughtonSE, NeroTL, et al. EPO does not promote interaction between the erythropoietin and beta-common receptors. Sci Rep. 2018;8(1):12457. doi:10.1038/s41598-018-29865-x30127368
   PubMed Web of Science ®Google Scholar
• NadamJ, NavarroF, SanchezP, et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol Dis. 2007;25(2):412–426. doi:10.1016/j.nbd.2006.10.00917166730
   PubMed Web of Science ®Google Scholar
• ZhangYL, RadhakrishnanML, LuX, GrossAW, TidorB, LodishHF. Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex. Mol Cell. 2009;33(2):266–274. doi:10.1016/j.molcel.2008.11.02619187767
   PubMed Web of Science ®Google Scholar